199
References:
1. Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG,
Bandello F, Corcostegui B, Cunha-Vaz J, Gaudric A, Leys A,
Schlingemann RO. Guidance for the treatment of neovascular
age-related macular degeneration. Acta Ophthalmol Scand 2007;
85 (5): 486-494.
2. Zuluaga MF, Mailhos C, Robinson G, Shima DT, Gurny R, Lange
N. Synergies of VEGF inhibition and photodynamic therapy in
the treatment of age-related macular degeneration. Invest Oph-
thalmol Vis Sci 2007; 48 (4): 1767-1772.
3. Markabi S. Combination therapy from the regulatory perspective.
Retina 2009; 29 (6 Suppl): S12-S14.
4. Karel I. Moznosti a ekonomické ukazatele lécby exsudativní vekem
podmínené makulární degenerace s choroidální neovaskulární
membránou. Cesk Slov Oftalmol 2007; 63 (5): 311-319.
5. Smiddy WE. Relative cost of a line of vision in age-related macular
degeneration. Ophthalmology 2007; 114 (5): 847-854.
6. Smiddy WE. Economic implications of current age-related macu-
lar degeneration treatments. Ophthalmology 2009; 116 (3): 481-
487.
7. Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevaci-
zumab and reduced light dose photodynamic therapy in age-relat-
ed macular degeneration: the VIA study. Br J Ophthalmol 2010;
94 (2): 174-179.
8. Augustin AJ, Offermann I. Gibt es eine medikamentöse Therapie
der altersbedingten Makuladegeneration?--Derzeitiger Stand und
neue therapeutische Ansätze. Klin Monbl Augenheilkd 2008; 225
(6): 555-563.
9. Funatsu H, Yamashita H, Sakata K, Noma H, Mimura T, Suzuki
M, Eguchi S, Hori S.Vitreous levels of vascular endothelial growth
factor and intercellular adhesion molecule 1 are related to diabetic
macular edema.Ophthalmology. 2005 May;112(5):806-16.
10. Butler JM, Guthrie SM, Koc M, Afzal A, Caballero S, Brooks HL,
Mames RN, Segal MS, Grant MB, Scott EW.SDF-1 is both nec-
essary and sufficient to promote proliferative retinopathy. J Clin
Invest. 2005 Jan;115(1):86-93.
11. Cidlowski JA. Glucocorticoids and their actions in cells. Retina
2009; 29 (6 Suppl): S21-S23.
12. Penfold PL, Wong JG, Gyory J, Billson FA. Effects of triamcinolo-
ne acetonide on microglial morphology and quantitative expres-
sion of MHC-II in exudative age-related macular degeneration.
Clin Experiment Ophthalmol 2001; 29 (3): 188-192.
13. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose
F, Musashi K, Yoshimura N. Intravitreal injection of corticoster-
oid attenuates leukostasis and vascular leakage in experimental dia-
betic retina. Invest Ophthalmol Vis Sci 2005; 46 (4): 1440-1444.
14. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of
crystalline cortisone as adjunctive treatment of proliferative vitre-
oretinopathy. Br J Ophthalmol 2000; 84 (9): 1064-1067.
15. Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neuro-
trophic factor. Nat Rev Neurosci 2003; 4 (8): 628-636.
16. Tombran-Tink J, Barnstable CJ. Therapeutic prospects for PEDF:
more than a promising angiogenesis inhibitor. Trends Mol Med
2003; 9 (6): 244-250.
17. Stahl A, Paschek L, Martin G, Feltgen N, Hansen LL, Agos-
tini HT.Combinatory inhibition of VEGF and FGF2 is supe-
rior to solitary VEGF inhibition in an in vitro model of RPE-
induced angiogenesis. Graefes Arch Clin Exp Ophthalmol. 2009
Jun;247(6):767-73. Epub 2009 Feb 27.
18. Niemz MH. Laser-tissue interactions: Fundamentals and applica-
tions. 1st Edition. Berlin, Germany. Springer. 1996; 1-297 p.
19. Henriques J, Brito LX, Neves CM, Vaz FT. Laser tissue interac-
tions. SPILM - Sociedade Portuguesa Interdisciplinar do Laser
Médico. Handbook of Pos Graduate course in medical laser 1998;
1.
20. Schmidt-Erfurth U, Kiss C, Sacu S. The role of choroidal hypop-
erfusion associated with photodynamic therapy in neovascular
age-related macular degeneration and the consequences for com-
bination strategies. Prog Retin Eye Res 2009; 28 (2): 145-154.
21. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung
CY, Kim RY; MARINA Study Group. Ranibizumab for neo-
vascular age-related macular degeneration. N Engl J Med 2006;
355(14): 1419-1431.
22. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim
RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab
versus verteporfin for neovascular age-related macular degenera-
tion. N Engl J Med 2006; 355 (14): 1432-1444.
23. ClinicalTrials.gov Identifier: NCT00492284
24. ClinicalTrials.gov Identifier: NCT00793923
25. ClinicalTrials.gov Identifier: NCT00390208
26. ClinicalTrials.gov Identifier: NCT00454389
27. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile
RC, Kotlovker D, Chung CY, Kim RY; FOCUS Study Group.
Ranibizumab combined with verteporfin photodynamic therapy
in neovascular age-related macular degeneration: year 1 results of
the FOCUS Study. Arch Ophthalmol 2006; 124 (11): 1532-1542.
28. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schnei-
der S, Shams N. Randomized, double-masked, sham-controlled
trial of ranibizumab for neovascular age-related macular degenera-
tion: PIER Study year 1. Am J Ophthalmol 2008; 145 (2): 239-
248.
29. Lalwani GA, Fung AE, Michels S, Dubovy SR, Feuer WJ Jr.,
Puliafito CA, Rosenfeld PJ. An OCT-guided variable-dosing regi-
men with ranibizumab (Lucentis) in neovascular AMD: two year
results of the PrONTO study. ARVO. Fort Lauderdale, USA, May
6-10, 2007. 2007; E-Abstract 1834-B694.
30. Koch F, Scholtz S, Singh P, Koss MJ. Kombinierte intravitreale
Therapie zur Behandlung der altersbedingten Makuladegenera-
tion. Klin Monbl Augenheilkd 2008; 225 (12): 1003-1008.
31. Shibuya M. Vascular endothelial growth factor receptor-1 (VEG-
FR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 2006;
9 (4): 225-230.
32. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M,
Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radzie-
Combined Treatment
